Company news
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) news
Atea Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 8, 2026: Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare…
Press releases & updates
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 8, 2026
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
August 5, 2026
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
July 27, 2026
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
July 14, 2026
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
June 24, 2026
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
May 26, 2026
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
May 13, 2026
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
May 5, 2026
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
February 26, 2026
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
February 24, 2026
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
December 22, 2025
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
November 19, 2025
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
November 7, 2025
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
November 5, 2025
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
October 22, 2025
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
October 7, 2025
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 2, 2025
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
July 31, 2025
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
June 24, 2025
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
May 7, 2025
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
May 1, 2025
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
April 23, 2025
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
April 17, 2025
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
April 9, 2025
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
March 26, 2025
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
March 21, 2025
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
March 19, 2025
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 6, 2025
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
February 27, 2025
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
February 24, 2025
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
December 15, 2024
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
December 3, 2024
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
November 14, 2024
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
October 30, 2024
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
September 12, 2024
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
August 27, 2024
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 6, 2024
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
June 4, 2024
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
May 21, 2024
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
May 6, 2024